1. Introduction {#s0005}
===============

Hereditary spastic paraplegias (HSP) constitute the second most common group of motor neuron diseases. They are characterized by progressive bilateral weakness, spasticity and the loss of vibration sensation in the lower limbs. These symptoms are mostly due to the degeneration of upper motor neuron axons in the corticospinal tracts ([@bb0050]). The main causes of autosomal recessive HSP are mutations in the *SPG11* gene. Symptoms of SPG11 patients generally appear during the first decade of life and, in addition to spastic gait disorder, include cognitive impairment, mental retardation, peripheral neuropathy, cerebellar ataxia, parkinsonism and retinal degeneration ([@bb0005], [@bb0115], [@bb0175]). These symptoms are often associated with progressive thinning of the *corpus callosum* and white matter hyperintensities by brain magnetic resonance imaging (MRI) ([@bb0055], [@bb0170]). Mutations in *SPG11* also account for autosomal-recessive Charcot Marie Tooth (CMT) disease ([@bb0090]) and slowly progressive juvenile-onset autosomal recessive amyotrophic lateral sclerosis (ALS) without cognitive impairment or abnormal MRI ([@bb0015], [@bb0100]). In agreement, a recent neuropathological analysis of the brain from two patients with the full-blown SPG11 phenotype showed that the pathology partially mimics ALS lesions ([@bb0020]).

*SPG11* encodes a 2443-amino acid protein called spatacsin. Regardless of the associated phenotype, the vast majority of mutations identified in SPG11 patients are nonsense or frameshift mutations, which are predicted to lead to the loss of function of spatacsin ([@bb0090], [@bb0100], [@bb0175]). The nature of the mutation is not responsible for the variability in phenotype as intrafamilial phenotypic variability has been observed, with the same mutations leading to juvenile ALS in one patient and HSP with a thin corpus callosum in his sibling ([@bb0015]).

Spatacsin interacts with proteins involved in membrane-trafficking ([@bb0060]), among which AP5Z1 (SPG48) and spastizin/zFYVE26 (SPG15) are also implicated in hereditary spastic paraplegia, when mutated ([@bb0045], [@bb0160]). The symptoms of patients mutated in the *SPG15* or *SPG11* gene are very similar ([@bb0045]), in agreement with their involvement in the same cellular mechanisms. Indeed, recent investigations in fibroblasts of SPG11 and SPG15 patients ([@bb0130]) and studies in mouse models have suggested that the loss of spatacsin or spastizin alters the function of the endolysosomal system ([@bb0070], [@bb0190]). Furthermore, spatacsin and spastizin have been shown to be involved in lysosome-recycling after fusion with autophagosomes in HeLa cells ([@bb0010]). In agreement, an *Spg11* knockout mouse model, obtained by inserting a genetrap cassette in the first intron of the *Spg11* gene, showed that the loss of spatacsin impairs autolysosome reformation, ultimately leading to depletion of lysosomes and impaired autophagic clearance ([@bb0190]). This Spg11 model reproduced the neurodegeneration in the motor cortex and cerebellum observed in SPG11 patients, but did not show any early-onset motor or cognitive deficits, amyotrophy or alterations of the *corpus callosum* as frequently observed in SPG11 patients.

We therefore extensively characterized a new *Spg11* knockout mouse model. These *Spg11*^*−/−*^ animals displayed early-onset motor and cognitive deficits as well as signs of peripheral neuropathy, recapitulating the human disease. These deficits were paralleled by neurodegeneration in the motor cortex, cerebellum, hippocampus, and spinal cord as well as alterations of neuromuscular junctions and muscular atrophy. This degeneration was accompanied by an accumulation of lipid material in lysosomal structures, similar to the observations made in human SPG11 brains ([@bb0020]). Investigation of primary cultures of mouse embryonic fibroblasts and cortical neurons showed that this accumulation was due to the loss of lipid clearance in lysosomes normally promoted by spatacsin.

2. Results {#s0010}
==========

We investigated the physiological role of spatacsin by disrupting the expression of *Spg11* in mice by inserting two successive stop codons in exon 32 of the gene ([Fig. 1](#f0005){ref-type="fig"}A), the most frequently mutated exon in SPG11 patients ([@bb0175], [@bb0170]). When heterozygous mice (*Spg11*^*+/−*^) were mated, knockout mice were generated in the expected Mendelian ratio and were viable. They developed normally, were fertile and had survival rates similar to those of their wild-type and heterozygous littermates (data not shown). We used Western blotting to verify that the disruption of the *Spg11* gene resulted in spatacsin depletion ([Fig. 1](#f0005){ref-type="fig"}B). Spatacsin has been shown to interact with spastizin/zFYVE26. Thus, we tested whether the loss of spatacsin affected spastizin expression levels. As observed in patient fibroblasts ([@bb0130]), spastizin levels in *Spg11*^*−/−*^ brain samples were 9.0% ± 3.8% (n = 3) of those of control (*Spg11*^*+/+*^) brain samples ([Fig. 1](#f0005){ref-type="fig"}B).

*Spg11*^*−/−*^ mice had no dysmorphic features or abnormalities up to the age of eight months relative to control littermates (data not shown). However, at 16 months, the age at which we stopped the study for ethical reasons, most of the knockout mice had an abnormal posture with spread hind limbs, lower pelvic elevation and pronounced kyphosis of the thoracic spine ([Fig. 1](#f0005){ref-type="fig"}C and D).

2.1. *Spg11*-knockout mice develop an early-onset motor deficit {#s0015}
---------------------------------------------------------------

We evaluated the consequences of the loss of function of spatacsin on motor functions by performing a series of complementary behavioral tests. From the age of four months onwards, *Spg11*^*−/−*^ mice displayed a progressive gait disorder and ataxia, which were quantified by recording the walking of mice on a treadmill at moderate speed (10 cm.s^− 1^) ([Fig. 2](#f0010){ref-type="fig"}A, B and C). This test showed that gait angle, the position of the hind paws relative to the axis of the body, was significantly higher in knockout mice than in control mice, from the age of four months onwards ([Fig. 2](#f0010){ref-type="fig"}A and B). With age, *Spg11*^*−/−*^ mice displayed a spreading of the hind limbs and began to drag their feet slightly during a forced walk (data not shown). We evaluated a possible ataxic gait by analyzing step sequence regularity, which reflects motor coordination. The regularity of the step sequence of *Spg11*^*−/−*^ mice was much lower than that of *Spg11*^*+/+*^ mice from eight months of age ([Fig. 2](#f0010){ref-type="fig"}C). The motor deficit was even more marked in the rotarod test, a forced-run-paradigm. *Spg11*^*−/−*^ mice displayed the first signs of motor impairment at the age of only six weeks in this test. The knockout mice remained on an accelerating rotarod for significantly less time than heterozygous and control mice, and could not reach the same maximum speed on the rotarod apparatus ([Fig. 2](#f0010){ref-type="fig"}D and E). This motor deficit worsened with time. Motor performance decreased with age in control and heterozygous mice, but was systematically better in these mice than in the knockout mice.

2.2. Loss of spatacsin causes a cognitive deficit in mice {#s0020}
---------------------------------------------------------

We subjected mice to the Y-maze spontaneous-alternation test to evaluate any cognitive deficits. This test relies on the tendency of mice to explore new environments and is used to monitor spatial memory ([@bb0065]) ([Fig. 2](#f0010){ref-type="fig"}F). During the first phase, mice were allowed to freely explore the only open arm of the maze and were confined there for one minute by closing a door behind them. During the second phase, they were placed at the entrance of the maze with both arms open. As expected, *Spg11*^*+/+*^ and *Spg11*^*+/−*^ mice naturally chose to explore the unknown arm of the maze, a new environment, in \~ 75% of the trials, rather than the part of the maze that had already been explored. In contrast, *Spg11*^*−/−*^ mice showed a lower tendency to enter the unknown arm than the *Spg11*^*+/+*^ mice at six weeks of age, and from four months on, the *Spg11*^*−/−*^ mice showed no preference between the visited and unknown arms ([Fig. 2](#f0010){ref-type="fig"}G), suggesting an alteration in short-term spatial working memory in the knockout mice. We performed a fear conditioning experiment, in which a neutral context was associated with two aversive electric shocks, to determine whether different types of memory were affected. Freezing normally reflects the stress behavior in response to an aversive stimulus. The freezing baseline slightly increased with age, but we observed no significant differences between knockout mice and wild-type or heterozygous littermates. The two electric shocks triggered a marked increase of freezing in all groups ([Fig. 2](#f0010){ref-type="fig"}H). The next day, the percentage of time that wild-type and heterozygous mice spent in a frozen posture without an electric shock was high, showing that the task was learned. In contrast, *Spg11*^*−/−*^ mice spent less time in a frozen posture from eight months on ([Fig. 2](#f0010){ref-type="fig"}I), suggesting that the knockout mice had a long-term emotional memory deficit.

2.3. Loss of spatacsin causes cortical, cerebellar and hippocampal atrophy {#s0025}
--------------------------------------------------------------------------

We investigated whether the observed behavioral phenotypes resulted from neurodegeneration by analyzing the cortex, cerebellum and hippocampus of *Spg11*^*−/−*^ mice. We measured the surface-areas of the brain and cortex on coronal brain sections (Bregma 0.90 to 0.60 mm) ([Fig. 3](#f0015){ref-type="fig"}A--E). The surface-area of the brain was lower in the *Spg11*^*−/−*^ than wild type mice only at 16 months ([Fig. 3](#f0015){ref-type="fig"}D), but the surface-area of the cortex was lower from eight months onwards ([Fig. 3](#f0015){ref-type="fig"}E). The surface-area of the *corpus callosum* was affected after only four months ([Fig. 3](#f0015){ref-type="fig"}F). We then determined the number of cortical neurons in the primary motor cortex by immunostaining coronal sections of the brain for NeuN ([Fig. 3](#f0015){ref-type="fig"}G, H, and I). The number of neurons in the cortical layers was unaffected in four-month-old *Spg11*^*−/−*^ mice, but from the age of eight months on, it was significantly lower than in *Spg11*^*+/+*^ mice ([Fig. 3](#f0015){ref-type="fig"}J and K). Neuronal degeneration worsened with time and was accompanied by astrogliosis, as shown by an increase in GFAP-positive cells ([Fig. 3](#f0015){ref-type="fig"}H, I, M, and N). We also observed increased levels of active caspase-3 in the cortex of *Spg11*^*−/−*^ mice, suggesting that neuronal death occurs *via* an apoptotic pathway ([Fig. 3](#f0015){ref-type="fig"}L).

Similarly, we measured the surface-areas of coronal sections of the cerebellum (Bregma − 6.00 to − 6.30 mm) ([Fig. 4](#f0020){ref-type="fig"}A) and showed that this structure was atrophied in *Spg11*^*−/−*^ mice from eight months on ([Fig. 4](#f0020){ref-type="fig"}B). Accordingly, the degeneration of Purkinje cells, labeled by Calbindin-immunostaining, followed a similar time course and was also accompanied by marked astrogliosis ([Fig. 4](#f0020){ref-type="fig"}C, D, and E).

As the *Spg11*^*−/−*^ mice displayed memory deficits, we examined the hippocampus by labeling neurons with anti-NeuN antibodies and astrocytes with anti-GFAP antibodies ([Fig. 4](#f0020){ref-type="fig"}G and H). We measured the surface-area of the hippocampus in brain coronal sections (Bregma − 1.70 to − 2.00 mm) ([Fig. 4](#f0020){ref-type="fig"}F). *Spg11*^*−/−*^ mice exhibited atrophy of the hippocampus relative to the control mice from four months on ([Fig. 4](#f0020){ref-type="fig"}G--I). The surface-areas of the granule layer of the CA1 region and the dentate gyrus were lower in the knockout than control mice from four months of age. The surface area of the granule layer in the CA2 and CA3 regions was lower in the *Spg11*^*−/−*^ than control mice only at 16 months of age ([Fig. 4](#f0020){ref-type="fig"}J--L). We observed no astrocyte proliferation in these structures.

2.4. *Spg11*^*−/−*^ mice show spinal cord atrophy and axonal degeneration in the corticospinal tract {#s0030}
----------------------------------------------------------------------------------------------------

We examined transverse, 0.5 μm semi-thin sections of cervical and lumbar spinal cords of mice of different ages by toluidine blue-staining ([Fig. 5](#f0025){ref-type="fig"}A and B). The surface-area and structure of the whole spinal cord of knockout and control mice were similar at four months of age. However, by 16 months of age, the whole spinal cord of *Spg11*^*−/−*^ mice showed significant atrophy compared to the *Spg11*^*+/+*^ mice (Cervical − 31,5%, lumbar − 29,2%) ([Fig. 5](#f0025){ref-type="fig"}A--F), as in the brain and cerebellum. Accordingly, at that stage, the surface-areas of the white and gray matter were lower in both the cervical and lumbar sections of *Spg11*^*−/−*^ spinal cords ([Fig. 5](#f0025){ref-type="fig"}E and F). At eight months of age, the surface-areas of the white and gray matter in the cervical section of knockout mice were similar to those of the control mice ([Fig. 5](#f0025){ref-type="fig"}C). In contrast, at that age, lumbar sections already showed the first signs of atrophy, with a slightly lower surface-area of the white matter than in controls ([Fig. 5](#f0025){ref-type="fig"}D).

We then assessed whether the degeneration of the cortico-spinal tracts that occurs in the human SPG11 disease, also occurs in *Spg11* knockout mice. We found that the distribution of the nervous fibers of the corticospinal tract was different in *Spg11*^*−/−*^ mice compared to that of *Spg11*^*+/+*^ mice ([Fig. 5](#f0025){ref-type="fig"}G and H). The percentage of small axons (\< 5 μm^2^) was significantly higher in *Spg11*^*−/−*^ mice from eight months of age than in age-matched controls ([Fig. 5](#f0025){ref-type="fig"}K). In parallel, the percentage of large axons (\> 15 μm^2^) was significantly lower in the knockout-mice. This pathological phenotype worsened with time ([Fig. 5](#f0025){ref-type="fig"}L). In addition, the corticospinal tract of knockout mice exhibited numerous dystrophic axons from eight months of age ([Fig. 5](#f0025){ref-type="fig"}H and N). On the contrary, the structure and organization of an ascending tract, the *cuneate fasciculus*, were similar between *Spg11*^*−/−*^ and *Spg11*^*+/+*^ mice of any age ([Fig. 5](#f0025){ref-type="fig"}I, J, M, and O).

2.5. Loss of spatacsin causes loss of lower motor neurons and myofibers {#s0035}
-----------------------------------------------------------------------

We evaluated the loss of spinal motor neurons by staining sections of lumbar spinal cord with an anti-choline acetyl transferase (ChAT) antibody ([Fig. 6](#f0030){ref-type="fig"}A and B). The number of motor neurons decreased in the spinal cord of *Spg11*^*−/−*^ mice from eight months onwards ([Fig. 6](#f0030){ref-type="fig"}C). Measurement of the cell body size in these neurons showed that the number of large motor neurons, with a surface-area \> 600 μm^2^, was lower in knockout animals, whereas the number of small motor neurons (\< 300 μm^2^) was unaffected ([Fig. 6](#f0030){ref-type="fig"}D--F). We then examined the neuromuscular junctions (NMJ) of the *soleus* muscle, staining the postsynaptic compartment with α-bungarotoxin and the presynaptic compartment with anti-neurofilament and anti-synaptophysin antibodies ([Fig. 6](#f0030){ref-type="fig"}G--I). The size of the NMJ decreased and the number of fragmented NMJs increased in *Spg11*^*−/−*^ mice from eight months on ([Fig. 6](#f0030){ref-type="fig"}J, and K). This alteration of NMJs was associated with slight and progressive atrophy of the *soleus* muscle from the age of eight months in *Spg11*^*−/−*^ mice ([Fig. 6](#f0030){ref-type="fig"}L and M). This atrophy resulted from a decrease in the number of myofibers in the *soleus* muscle of *Spg11*^*−/−*^ mice and a slight decrease in their surface-area ([Fig. 6](#f0030){ref-type="fig"}N and O), suggesting that these animals exhibit progressive amyotrophy. We observed similar results in the *tibialis* and *plantaris* skeletal muscles (data not shown). Accordingly, a grip test that measures traction strength showed that *Spg11*^*−/−*^ mice lost muscular strength in both forelimbs and hind limbs from 12 months on ([Fig. 6](#f0030){ref-type="fig"}P).

2.6. Loss of spatacsin leads to early lysosomal dysfunction {#s0040}
-----------------------------------------------------------

We then evaluated the cellular alterations underlying neurodegeneration in *Spg11*^*−/−*^ mice. Autofluorescent intracellular material accumulated in the neurons of the cerebral cortex in *Spg11*^*−/−*^ mice. We observed this accumulation in six week-old knockout mice, whereas large autofluorescent particles were not detected until the age of 16 months in control mice. At this stage, the deposits in the motor neurons of knockout mice were more numerous and larger than those in control mice (Fig. Sup 1A). We did not detect autofluorescence upon excitation at 635 nm (Fig. Sup 1B), so it was possible to analyze its colocalization with various markers. Lamp1 immunoreactivity surrounded the autofluorescent aggregates ([Fig. 7](#f0035){ref-type="fig"}A), suggesting that the loss of spatacsin altered lysosomal function. Lysosomes play a key role in autophagosome degradation, and lysosomal dysfunction is thought to lead to the accumulation of autophagolysosomes ([@bb0080]). We therefore investigated whether the autofluorescent aggregates colocalized with p62, a marker of autophagy substrates. We observed colocalization of p62 with autofluorescent aggregates only in *Spg11*^*−/−*^ mice at 16 months of age ([Fig. 7](#f0035){ref-type="fig"}B). We observed similar autofluorescent aggregates surrounded by Lamp1 immunostaining in Purkinje cells in the cerebellum (Fig. Sup 2A and B) and in spinal motor neurons (data not shown) of 16 month-old *Spg11*^*−/−*^ mice. The autophagy marker p62 also colocalized with the autofluorescent aggregates in Purkinje cells of *Spg11*^*−/−*^ mice from the age of eight months (Fig. Sup 2C). These data suggest that autophagic substrates accumulate in lysosomal structures in the cerebral and cerebellar cortex and in spinal motor neurons in *Spg11*^*−/−*^ mice, but only at late stages of the disease. We further investigated changes in autophagy by carrying out Western blotting to determine the levels of LC3-II, the lipidated form of LC3 recruited to autophagosomes. LC3-II levels were similar in control and knockout mice, at all ages ([Fig. 7](#f0035){ref-type="fig"}C). Thus, spatacsin loss led to the accumulation of the p62 autophagic marker, but this accumulation seems to be only a late event in the disease process.

We analyzed cortical and spinal neurons by electron microscopy to confirm the alteration of lysosomal function in the brain and spinal cord of *Spg11*^*−/−*^ mice ([Fig. 8](#f0040){ref-type="fig"}). Lysosomes appeared as electron-dense organelles surrounded by a membrane. We observed in the cortical neurons of two-month old knockout animals lysosomes containing osmiophilic material, suggesting the presence of undigested material ([Fig. 8](#f0040){ref-type="fig"}A). These lysosomes also contained low-density structures that are consistent with lipid droplets ([Fig. 8](#f0040){ref-type="fig"}A). The size of these lipofuscin-like particles strongly increased with age, as did the size of lysosomes containing autofluorescent material ([Fig. 8](#f0040){ref-type="fig"}A). We also observed similar lysosomes in spinal motor neurons, Purkinje cells and hippocampal neurons of *Spg11*^*−/−*^ mice from the age of two months ([Fig. 8](#f0040){ref-type="fig"}Band data not shown). These structures were positive for cathepsin D, suggesting a lysosomal origin ([Fig. 8](#f0040){ref-type="fig"}C). Similar structures have been observed in a large number of cortical neurons in the brain of an SPG11 patient ([@bb0020]) carrying two truncating heterozygous mutations in *trans* ([Fig. 8](#f0040){ref-type="fig"}D), suggesting that they contribute to the neuropathological process. The significant increase in lipid-containing structures in *Spg11*^*−/−*^ neurons, even in young animals, suggests that lipid clearance by lysosomes may be impaired.

2.7. Spatacsin promotes the clearance of lipids from lysosomes {#s0045}
--------------------------------------------------------------

We investigated the cellular alterations underlying lysosomal dysfunction in the brains of *Spg11*^*−/−*^ mice by studying primary cultures of mouse embryonic fibroblasts and cortical neurons by electron microscopy. The proportion of lysosomes containing osmiophilic material was significantly higher in *Spg11*^*−/−*^ fibroblasts ([Fig. 9](#f0045){ref-type="fig"}A and B) and neurons ([Fig. 10](#f0050){ref-type="fig"}A and B), as observed in the brains of *Spg11* knockout mice and human SPG11 patients. We tested whether lysosomes accumulated lipidic material, by labeling lysosomes in fibroblasts and neurons with the Lamp1 antibody and total lipids with Nile red, which stains all neutral and polar lipids ([@bb0040]). The proportion of Nile red staining colocalized with lysosomes was higher in *Spg11*^*−/−*^ fibroblasts ([Fig. 9](#f0045){ref-type="fig"}C and D) and cortical neurons ([Fig. 10](#f0050){ref-type="fig"}C and D) than control cells, confirming the accumulation of lipids in lysosomes in both these cell types under basal conditions.

Material may accumulate in lysosomes due to changes in lysosomal pH or the inhibition of lysosomal proteolytic activity. The lysosomal pH was 4.59 ± 0.19 in control fibroblasts and 4.53 ± 0.21 in *Spg11*^*−/−*^ fibroblasts (n = 500 cells per replicate, 5 independent experiments performed in quadruplicate) as measured using the Lysosensor Green probe. Cathepsin B activity, monitored with the Magic Red Cathepsin B substrate, was not affected by the absence of spatacsin (data not shown). These data suggests that the accumulation of lipids in lysosomes of *Spg11*^*−/−*^ fibroblasts or neurons was not due to changes in lysosomal pH or cathepsin B activity.

We hypothesized that spatacsin could play a role in the clearance of lipids from lysosomes. It has been suggested that autophagy shuttles phospholipids of organelle membranes into lysosomes, and that fatty acids hydrolyzed by the lysosomes then accumulate in lipid droplets ([@bb0120]). We investigated whether autophagy induction affected the accumulation of lipids in lysosomes by monitoring Nile red and Lamp1 staining. We observed an accumulation of lipids in lysosomes two and six hours after amino-acid deprivation, followed by lipid clearance from lysosomes and the accumulation of lipid droplets ([Fig. 9](#f0045){ref-type="fig"}C and D). Inhibition of lysosomal enzymes by pH neutralization with bafilomycin A1 blocked lipid clearance from the lysosomes, confirming that lipid clearance from lysosomes occurred actively (data not shown). Lipids were cleared significantly more slowly from the lysosomes of *Spg11*^*−/−*^ fibroblasts than control cells, suggesting a role for spatacsin in lysosomal lipid clearance ([Fig. 9](#f0045){ref-type="fig"}D). Consistent with these findings, the number of lipid droplets was smaller in *Spg11*^*−/−*^ than control cells after 24 h of amino-acid starvation ([Fig. 9](#f0045){ref-type="fig"}E). In untreated cells, the number of lipid droplets was also smaller in *Spg11*^*−/−*^ fibroblasts or primary cortical neurons than in control cells ([Figs. 9](#f0045){ref-type="fig"}E and [10](#f0050){ref-type="fig"}E), also suggesting a role for spatacsin in the clearance of lipids from lysosomes under basal conditions.

3. Discussion {#s0050}
=============

Loss of function mutations in *SPG11* cause a large variety of phenotypes ranging from pure to complex forms of motor neuron diseases, including pure forms of HSP, juvenile-onset ALS or CMT and complex forms of HSP associated with mental impairment or cognitive decline, neuropathy and abnormal MRI features ([@bb0090], [@bb0100], [@bb0175]). The most striking and common clinical hallmark observed in SPG11 patients is gait disturbance with motor difficulties generally developing in the two first decades of life. Most patients display progressive spasticity of the lower limbs associated with severe muscular weakness. In the *Spg11*^−/−^ mouse model generated in this study, behavioral tests revealed progressive gait impairment and motor dysfunction, beginning at the age of six weeks, consistent with the first symptoms detected in human patients before the age of 10 years. This phenotype was associated with progressive neurodegeneration in the motor cortex and cerebellum, as well as the presence of dystrophic axons in the corticopinal tract. SPG11 patients also frequently present peripheral neuropathy associated with distal muscle wasting, in particular when diagnosed with juvenile-onset ALS or CMT. In agreement, the *Spg11*^−/−^ mouse model described here also presented a progressive loss of large motor neurons in the gray matter of the lumbar spinal cord and a high proportion of fragmented neuromuscular junctions. This degeneration together with the loss of muscular strength in 12-month old *Spg11*^−/−^ mice is consistent with a late ALS-like phenotype in the *Spg11* mouse model. However, the homogenous decrease in the cross section of myofibers in *Spg11*^−/−^ mice suggests that muscular atrophy was not a consequence of denervation of individual fibers. Spatacsin may thus play a more general role in muscle physiology, and the loss of function of this protein could directly result in muscular atrophy. Our observation in the *Spg11*^−/−^ mouse model is also consistent with the mental impairment observed in most SPG11 patients and the worsening cognitive decline as the disease progresses ([@bb0155], [@bb0175], [@bb0165]). The cognitive impairment in the mouse was associated with the early atrophy of the hippocampus.

The *Spg11* mouse model we characterized develops motor deficits much earlier than the *Spg11*-knockout mouse developed by [@bb0190]. We also observed degeneration of lower motor neurons and thinning of the *corpus callosum* that were absent in the model of [@bb0190], as well as cognitive impairment that was not reported. The discrepancies between the two models may be due to the strategy used to inactivate *Spg11*. Varga et al. inactivated *Spg11* by inserting a genetrap cassette in the first intron of the gene, whereas we inserted stop codons in exon 32 to mimic the most frequent mutation observed in SPG11 patients ([@bb0055], [@bb0175]). The effects of these two types of mutations on some spatacsin isoforms may account for the differences in the results obtained by these two studies. The construct used by [@bb0190] was predicted to encode a cytoplasmic fusion protein of the 82 N-terminal amino acids of spatacsin with βgeo ([@bb0190]). We could not verify whether the insertion of stop codons in exon 32 led to the production of a truncated protein or complete degradation of the mutant protein, because the antibody we used recognizes the C-terminal domain of spatacsin. The difference between the two studies reflects the remarkable range of phenotypes observed in humans. Indeed, no genotype-phenotype correlation has been shown in SPG11 patients. The same mutations can lead to different phenotypes in the same family ([@bb0015]) and mutations in different parts of the *SPG11* gene lead to the same pathology ([@bb0175], [@bb0170]). Other factors, such as environmental, genomic, or epigenetic factors, may contribute to the variability of phenotypes found in SPG11 patients, and could contribute to the difference in the phenotype observed between our *Spg11* mouse model and that developed by [@bb0190].

Histological and electron microscopy analyses showed the presence of cellular dysfunction in young animals, before neuronal death occurred. In the neurons of *Spg11*^−/−^ animals, we observed autofluorescent particles that were surrounded by the lysosomal marker Lamp1 and organelles that contained lipidic material by electron microscopy. The size of both markers increased with age, suggesting that they are the same structure. There was no significant difference in the levels of the autophagy marker LC3-II in brains of the *Spg11*^−/−^ mice relative to controls. It is however possible that mild changes in the autophagy pathway occur during disease progression, explaining the large accumulation of lipids and p62 in lysosomes in 16-month-old *Spg11*^*−/−*^ mice, as well as in the brains of SPG11 patients ([@bb0020]).

Our data show that lipids accumulate in lysosomes very early in development. Indeed, they were already detected in cultured *Spg11*^*−/−*^ fibroblasts and neurons obtained from embryos. This may contribute in the long term to the generation of lipofuscin that has been proposed to be composed of numerous lipid species ([@bb0180]). How the loss of spatacsin function leads to the accumulation of lipids in lysosomes remains to be determined. The absence of spatacsin did not alter lysosomal pH nor impair cathepsin B catalytic activity. Artificial activation of autophagy in mouse embryonic fibroblasts resulted in the transient accumulation of lipids in lysosomes and the formation of lipid droplets, as observed in other models ([@bb0120]). The clearance of lipids from lysosomes was lower in absence of spatacsin, which may account for the slight accumulation of lipids in lysosomes and the smaller number of lipid droplets at steady state. We were unable to promote lipid accumulation in lysosomes upon starvation in cultured neurons, because they do not respond to this stimulus (data not shown), as previously reported ([@bb0085]). Nevertheless, the change in lipid metabolism was evident under basal conditions, suggesting that the loss of spatacsin function impaired lipid clearance from lysosomes in neurons as well.

The mechanism for spatacsin-mediated clearance of lipids from lysosomes remains enigmatic, especially as the precise subcellular localization of spatacsin is still debated ([@bb0010], [@bb0070], [@bb0140], [@bb0160], [@bb0185]). We hypothesize that spatacsin acts as a lipid transporter as it has been proposed to have transmembrane regions ([@bb0170]) and has been found to be localized in lysosomes ([@bb0060]). Alternatively, the proposed role of spatacsin in autolysosome reformation ([@bb0010]) could play a role in sorting lipids within lysosomes. However, it was not possible to evaluate whether these tubular lysosomal structures contained lipids, detected by Nile Red staining, because of their small diameter. The absence of spatacsin function may also deregulate lysosomal protein machinery implicated in lipid egress, which remains to be identified, possibly through a disturbance in membrane-trafficking, which is altered in SPG11 cells ([@bb0110]).

Regardless of the molecular mechanism involved, the loss of spatacsin function resulted in the presence of fewer lipid droplets. Changes in lipid droplet metabolism have been reported for other proteins associated with the physiopathology of HSP, such as spastin, atlastin1, REEP1 and spartin ([@bb0030], [@bb0075], [@bb0105], [@bb0135], [@bb0125]). It would be informative to investigate whether the changes in lipid droplet number or size reflect changes in lysosome-mediated lipid trafficking in these models, as in the *Spg11*^*−/−*^ mouse model. Proteins linked to the biogenesis of lipid droplets were identified as neurotoxicity modifiers associated with VAPB, a gene mutated in ALS8 ([@bb0145]). It would be worthwhile to investigate whether lysosomal function and lipid droplet metabolism are also altered in various ALS mouse models to better understand the overlap between SPG11/ALS5 and typical ALS pathology.

In conclusion, the *Spg11*^*−/−*^ mouse model presented here recapitulates the full set of symptoms observed in human HSP, CMT and juvenile-onset ALS and is therefore a good model to investigate the mechanisms underlying their physiopathology. Examination of the cellular alterations observed in this model suggests that the loss of spatacsin function alters lipid metabolism in lysosomes. Our study therefore links two of the main themes, lysosome dysfunction and lipid metabolism, that are recurrent in the function of proteins encoded by the numerous genes associated with HSP and opens common avenues of research for future therapy linked to lipid turnover.

4. Methods {#s0055}
==========

4.1. Generation and breeding of Spg11 knockout mice {#s0060}
---------------------------------------------------

*Spg11*-knockout mice were generated as previously described ([@bb0150]). The gene targeting vector was constructed by inserting a fragment corresponding to mouse exon 32 to exon 34 (sv129 genetic background) into intron 34 in an inverse orientation, with c.6052C \> T and c.6061C \> T substitutions in exon 32 ([Fig. 1](#f0005){ref-type="fig"}A). MCI-129Sv/Pas ES cell lines were transfected with the resulting construct and screened by Southern blotting and PCR. Homologous recombinant clones were injected into blastocysts. Chimeric mice were mated with C57BL/6 females to obtain germline transmission. The Neo selection cassette was removed by crossing with a *flp*-expressing mouse. The ubiquitous insertion of exon 32-bearing stop mutations was achieved by crossing the mice with a line expressing Cre recombinase under the control of the CMV promoter. Heterozygous mice were then backcrossed with C57BL/6N mice for 10 generations.

Genotyping was performed by PCR with the 5′GCCAAGGTATGCACCAGACGGGG3′ and 5′TCCTGCCCTTCACCACGTCAGG3′ primers. PCR products of 493 and 434 bp were obtained for the invalidated and wild-type alleles, respectively. Mice were housed in same-sex groups and maintained on a 12-h light/12-h dark cycle with unrestricted access to food and water.

4.2. Behavioral evaluation {#s0065}
--------------------------

At least 10 animals per genotype and per age were tested. All behavioral procedures were performed between 8:00 a.m. and 1:00 p.m. Bias was minimized by randomly testing mice in experimental cohorts, regardless of their genotype. The treadmill test was performed with an apparatus consisting of a plastic chamber containing a 4 × 16 cm treadmill (CleverSys). The mice were tested individually at a controlled speed of 10 cm·s^− 1^. After a 1-min habituation phase, the gait of the mice was recorded for 20 s (80 frames per s, BCam). Gait was analyzed using GaitScan software (CleverSys). The motor deficit was also evaluated with a Rotarod apparatus (accelerating model LE8200, Bioseb). Mice were placed on the accelerating rod at a starting speed of 4 rpm. The final speed of 40 rpm was reached within 5 min. Mice were tested on two consecutive days, in five trials per day, with an interval of 15 min between trials. The duration for which they were able to remain on the rod was recorded.

Cognitive function was monitored using the Y-maze and fear conditioning tests. The Y-maze consists of three transparent arms of equal length separated by the same distance (40 cm long, 20 cm high, 10 cm wide, 120°). Visual cues are placed in the room. One arm of the maze (arm B) was blocked by a removable opaque partition and the mice were placed individually in the starting arm (arm A) of the apparatus facing the center of the maze. The mouse was allowed to walk freely into the maze. When it arrived at the end of the open arm (arm C), the partition was put in place retaining the mouse. After 1 min, the mouse was immediately placed in the starting arm again (arm A), and the partition was removed to offer two choices. Alternation was defined as spontaneous entry into the unvisited arm (arm B). On the contrary, re-entry into the already explored arm (arm C) was considered to be an error. Contextual fear conditioning was performed in a Plexiglas chamber (17 × 17 × 25 cm) placed in a sound-attenuating box (Fear Conditioning Systems Series 46000, Ugo Basile SRL Comerio Italy). The walls of the chamber are covered by a removable checkerboard context. The bottom of the chamber is composed of a stainless steel grid floor (rods were 2 mm in diameter and spaced 1 cm apart) connected to a scrambled shock generator. Training was initiated by placing the mice in the training context and the freezing baseline was scored during the first 120 s. Then, two electric shocks (2 s, 0.62 mA spaced by 60 s) were delivered under the control of AnyMaze software. The end of the training session consisted of a 120 s period during which freezing was recorded. Contextual fear conditioning was tested 24 h after training by returning mice to the training chamber and scoring freezing for 180 s without electrical shocks.

Muscle strength was recorded with a grip test system (Dual Sensor 1027CD-M, Colombus, Linton Instrumentation). When the animal firmly gripped the triangular metal rod, the experimenter gently pulled its tail horizontally until the animal released its hold. The maximum traction force (mN) developed by the forelimbs and hindlimbs was recorded.

4.3. Antibodies {#s0070}
---------------

Antibodies used in the study were: rabbit anti-spatacsin (Protein Tech, directed against aa 2094--2443 of human spatacsin); rabbit anti-spastizin ([@bb0095]); mouse anti-α-tubulin (Abcam); mouse anti-NeuN (Millipore); rabbit anti-GFAP (DAKO); monoclonal mouse anti-Calbindin, 1:300, (Swant); goat anti-Choline acetyltransferase (ChAT), 1:500, (Millipore); rabbit anti-Neurofilament-L, 1:100, (Millipore); mouse Alexa Fluor® 488 conjugated anti-Synaptophysin, 1:25, (Millipore); rat anti-Lamp1 (Clone 1D4B), mouse anti-p62 (Abcam); rabbit anti-LC3 (Novus Biologicals); goat anti-caspase-3 (Millipore). For immunoblotting, the secondary antibodies were conjugated to horseradish peroxidase (Jackson Laboratories) or fluorochromes (IR-dye 800 or IR-dye 680; LI-COR). Secondary antibodies used for immunofluorescence were purchased from Life Technologies.

4.4. Histological and immunohistochemical analyses {#s0075}
--------------------------------------------------

Mice were anesthetized by the intraperitoneal injection of 1/6 2% xylazine (Rompun), 1/3 ketamine (10 mg·ml^− 1^, Imalgen 1000) in phosphate-buffered saline (PBS) and were subjected to intracardiac perfusion of 4% paraformaldehyde in PBS.

For immunostaining analysis, the brains and spinal cords were dissected and post-fixed by incubation for 24 h in 4% paraformaldehyde and 24 h in 30% sucrose PBS. Slices (20 μm for brain and 40 μm for lumbar spinal cord) were cut on a freezing microtome (Microm HM450, Thermo Scientific) and maintained in 0.02% sodium azide in PBS at 4 °C. After 90 min incubation in blocking solution, sections were incubated with primary antibodies in 2% BSA/0.25% Triton X-100 in PBS overnight at 4 °C. After washing, the sections were incubated with the secondary antibodies for 90 min at room temperature, and mounted in Fluoromount-G mounting medium (Southern Biotechnology). Staining specificity was determined by incubation in the absence of primary antibodies.

Whole-mount preparations of muscle fibers were stained for motor endplates with Alexa Fluor® 555-conjugated α-bungarotoxin 1:500 (Life technologies) and for presynaptic motor nerve terminals with anti-Neurofilament L and anti-Synaptophysin antibodies in 2% BSA/0.5% Triton X-100 Glycin 0.15% in PBS 48 h at 4 °C. After washing, the sections were incubated with the secondary antibodies for 60 min at room temperature, and mounted in Fluoromount-G mounting medium (Southern Biotechnology).

For morphological analysis, cervical (C1 to C7) and lumbar (L1 to L5) parts of the spinal cords were placed in 2% glutaraldehyde for 24 h. They were then embedded in EPON resin and 1 μm-thin sections were stained with toluidine blue for 1 h.

For muscle typology, *soleus* muscles were frozen into NEG-50™ (Thermo Scientific) at − 60 °C. Transversal sections (10 μm) of the medial part of the muscle were prepared with a Leica CM3050S cryostat and stained with Hematein for 3 min and Eosin for 1 min.

The surface-areas of the brains or brain regions were determined using NDPview software. Counting of cell populations was performed using ImageJ software. Spinal motor neuron, neuromuscular junction, and corticorspinal tract images were collected with a Leica DFC500 camera mounted on a Leica DM4000B microscope with 40 ×, 60 × and 100 × objectives. Whole spinal cord and muscle Images were obtained with a NanoZoomer 2.0-RS (Hamamatsu) equipped with a 20 × objective. Identical brightness, contrast and colour balance adjustments were applied to all groups. Confocal images were acquired with an Olympus FV-1000 confocal laser scanning microscope, with a 60 × objective. Autofluorescence was triggered by excitation with a 488 nm laser.

4.5. Cell biology {#s0080}
-----------------

Mouse embryonic fibroblasts and primary cultures of cortical neurons were prepared as previously described ([@bb0035]). Immunostaining was performed after six days of culture *in vitro*, as previously described ([@bb0095]). For lipid staining, cells were incubated for 1 h with Nile Red (1 μg/ml) in PBS, and then washed three times in PBS. Images were acquired on an inverted Zeiss Axiovert 200 M microscope and processed using Huygens deconvolution software. ImageJ was used to quantify the colocalization of Nile Red staining with lysosomes. Lipid droplets were stained either with Bodipy 493/503 (Life Technologies) or Nile Red. Their number and size were analyzed using the spot detector of ICY software.

Cathepsin B catalytic activity and lysosomal pH were quantified on an automated ArrayScan XTI apparatus (Thermo-Fisher) using the General Intensity Measurement protocol, analyzing \> 500 cells per well and per set of conditions. Fibroblast detection was facilitated by incubation with Cell Tracker Deep Red (Life Technologies) in HCSS (0.12 M NaCl, 5.4 mM KCl, 15 mM glucose, 2 mM CaCl~2~, 0.7 mM MgCl~2~, 20 mM Hepes, pH 7.4) for 30 min. Cathepsin B activity was determined with the Magic Red Cathepsin B Assay Kit, according to the manufacturer\'s instructions (ImmunoChemistry Technologies). Lysosomal pH was determined by incubating the cells with Lysosensor Green (Life Technologies) in HCSS for 1 h. Fluorescence intensity was compared with that of cells incubated in calibration solutions with a pH ranging from 3.5 to 6. For calibration, cells were incubated for 30 min in 145 mM KCl, 10 mM glucose, 1 mM MgCl~2~, and 20 mM MES supplemented with 5 μM nigericin (Sigma) and 0.25 μM valinomycin (Sigma), with artificial adjustment of the pH. Fluorescence was converted into pH values by curve fitting.

4.6. Electron microscopy {#s0085}
------------------------

Briefly, mice were anesthetized and sacrificed by intracardiac perfusion with a solution of 4% paraformaldehyde in 0.1 M phosphate buffer at pH 7.4. Samples from the frontal cortex and spinal cord were fixed in 1% glutaraldehyde in the same buffer, post-fixed in 2% osmium tetroxide, dehydrated, and embedded in Araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and examined by a Hitashi transmission electron microscope. To analyze cultured fibroblasts and neurons, cells were fixed with 2.5% glutaraldehyde in PBS for 2 h at 22 °C. The cells were then post-fixed in 1% osmium tetroxide for 20 min, rinsed in distilled H~2~O, dehydrated in 50% and 70% ethanol, incubated in 1% uranyl acetate for 30 min, processed in graded dilutions of ethanol (95--100%, 5 min each), and embedded in Epon. Ultrathin (70 nm) sections were cut, stained with uranyl acetate and lead citrate, and analyzed with a JEOL 1200EX II electron microscope at 80 kV.

4.7. Western blot analysis {#s0090}
--------------------------

Cells or tissues were lysed by incubation in 100 mM NaCl, 10 mM Tris HCl pH 7.4, 1 mM EGTA, 2 mM MgCl~2~, 1% SDS, and Halt™ Protease Inhibitor Cocktail (Thermo Scientific) for 5 min at room temperature. Western blotting was performed as described previously ([@bb0025]). Signals were visualized with a chemiluminescence substrate (SuperSignal West Dura), or acquired with an Odyssey ClX (Li-COR). Signal intensities were quantified using ImageJ software.

4.8. Statistics {#s0095}
---------------

All values are displayed as the means ± SEM within each group. A Kolmogorov--Smirnov normal distribution analysis was first performed on all data. Data sets were compared using the Kruskal--Wallis test for nonparametric data sets and the 2-tailed Student\'s *t*-test for parametric data sets (Systat version 8.0; SPSS Inc., Chicago, IL, USA). For cellular experiments, two-way ANOVA followed by the Holm Sidak test was used to analyze differences between genotypes at different time points. A p value of 0.05 or less was considered to be statistically significant.

4.9. Study approval {#s0100}
-------------------

The care and treatment of animals followed the N° 2010/63/UE European legislation and national authority (Ministère de l\'agriculture, France) guidelines for the detention, use, and ethical treatment of laboratory animals. All the experiments were approved by the local ethics committee (Ce5/2012/045 approval number) and experiments were conducted by authorized personnel. Patient-derived material was obtained through procedures approved by the ethics committee with the written, informed consent of the family (approval SST04/11/04052011).
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![*Spg11* knockout causes a progressive motor deficit in mice. (A). Diagram showing the genomic structure of the *Spg11* gene (top), the targeting vector (middle) and the targeted locus upon excision of the neomycin resistance cassette and action of the Cre-recombinase (bottom). The mutations introduced were c.6052C \> T (p.Arg2018\*), corresponding to c.6091C \> T (p.Arg2031\*) in human and c.6061C \> T (p.Gln2021\*), corresponding to c.6100C \> T (p.Arg2034\*) in human. (B) Western blot of brain protein extracts showing the absence of spatacsin in *Spg11*^*−/−*^ samples and the strong decrease in the levels of spastizin. Representative image of three independent experiments. \* : non-specific band. (C and D), Pictures showing an *Spg11*^*+/+*^ (C) and *Spg11*^*−/−*^ mouse (D) at 16 months of age. Knockout mice had an abnormal posture and kyphosis of the spine.](gr1){#f0005}

![*Spg11* knockout mice develop a progressive spastic and ataxic gait disorder. (A and B) Gait angle sketch (A) and values recorded (B) during a forced walk on a treadmill. The gait angle decreased in *Spg11*^*−/−*^ mice from four months of age (n ≥ 12 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05 and \*\*\*p ≤ 0.001). (C) Step sequence regularity values recorded during a forced walk on a treadmill. *Spg11*^*−/−*^ mice exhibited motor coordination impairment from eight months of age (n ≥ 12 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001). (D and E) Rotarod duration (D) and maximum speed (E). The duration and maximum speed of *Spg11*^*−/−*^ in accelerated rotarod testing was less than those of heterozygous and control mice at as early as six weeks of age (n ≥ 12 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05, \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001). (F and G) The Y-maze principle (F) and spontaneous alternation values (G). Knockout mice did not show a preference between the visited and the unknown arm of the maze from four months of age (n ≥ 12 animals/genotype/age; Kruskal-Wallis test; \*\*\*p ≤ 0.001). This altered cognitive behavior underlines a spatial learning or a memory deficit. (H and I) Fear conditioning. Percentage of time spent in a frozen posture on day 1 before and after electrical shocks (H). There was no obvious learning deficit during the conditioning of the mice at any age. Percentage of time spent in a frozen posture on day 2, without any electrical shocks, after conditioning (I). Although the task was learned, knockout mice spent less time in a frozen position from eight months of age, indicating a cognitive and memory deficit (n ≥ 10 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001).](gr2){#f0010}

![Loss of spatacsin causes severe cortical damage. (A and B) Brain coronal slices of *Spg11*^*+/+*^ (A) and *Spg11*^*−/−*^ (B) mice at 16 months of age. GFAP (green; astrocyte marker), and NeuN (magenta; neuronal marker) immunostaining. Scale bars: 1 mm. (C) Sagittal view of mouse brain showing the location of the coronal cut sections between Bregma 0.90 and 0.60 mm. (D--F) Brain (D), cortex (E) and corpus callosum (F) surface-areas. The surface-areas of the cortex and *corpus callosum* decreased from eight and four months, respectively, prior to general brain atrophy (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05 and \*\*\*p ≤ 0.001). (G) Diagram of the primary motor cortex layers between Bregma 0.90 and 0.60 mm. (H and I) NeuN (magenta) and GFAP (green) immunostaining in the primary motor cortex of *Spg11*^*+/+*^ (H) and *Spg11*^*−/−*^ (I) mice at 16 months of age. Scale bars: 200 μm. (J and K) Quantification of total NeuN-positive cells in the primary motor cortex layers I + II + III (J) and V + VI (K). Immunostaining revealed a significant reduction in the number of neurons from layers I--VI of the motor cortex in knockout mice from eight months of age. (n ≥ 10 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001). (L) Western blot of 16-month-old *Spg11*^*+/−*^ and *Spg11*^*−/−*^ brain samples showing the presence of cleaved (active) caspase-3 in the absence of spatacsin. (M and N) Quantification of total GFAP-positive cells in the primary motor cortex layers I + II + III (M) and V + VI (N). Neuron loss was accompanied by marked astrogliosis (n ≥ 10 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*\*\*p ≤ 0.001).](gr3){#f0015}

![Loss of spatacsin causes cerebellar and hippocampal impairment. (A) Sagittal view of mouse brain showing the location of the coronal cut sections between Bregma − 6.00 and − 6.30 mm. (B) The surface-area of the cerebellum was lower in the knockout than in the control mice from eight months. (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05). (C) The number of Purkinje cells was lower from eight months of age in knockout mice (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*\*\*p ≤ 0.001). (D and E) Cerebellar sections immunostained for GFAP (green; astrocyte marker), Calbindin (magenta, Purkinje cell marker), and Hoechst-33258 (blue, nucleus marker) revealed a severe loss of Purkinje cells in knockout mice (E) compared to control mice (D). Scale bars: 100 μm. PCL: Purkinje Cell Layer. (F) Sagittal view of mouse brain showing the location of the coronal cut sections between Bregma − 1.70 and − 2.00 mm. (G--H) NeuN (magenta; neuronal marker) and GFAP (green; astrocyte marker) immunostaining in the hippocampus of *Spg11*^*+/+*^ (G) and *Spg11*^*−/−*^ (H) mice at 16 months of age. Scale bars: 0.5 mm. CA1: *cornu Ammonis* 1 region, CA2: *cornu Ammonis* 2 region, CA3: *cornu Ammonis* 3 region, DG: Dentate Gyrus region. (I) Hippocampal surface-area. The surface-area of the hippocampus was smaller in knockout than control mice at all ages (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05). (J--L) CA1 (J), CA2 + CA3 (K), and dentate gyrus (L) granule layer surface-areas. The surface-area of CA1 and the dentate gyrus granule layer were affected by atrophy from four months of age in knockout mice compared to control mice (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05).](gr4){#f0020}

![*Spg11*^*−/−*^ mice show spinal cord atrophy and axonal degeneration of the corticospinal tract. (A and B) Toluidine blue-stained transverse slices of *Spg11*^*+/+*^ (A) and *Spg11*^*−/−*^ (B) mouse cervical spinal cord at 16 months of age. Scale bars: 0.5 mm. GM: gray matter, WM: white matter. (C--F) Surface-areas of the white and gray matter of the cervical (C and E) and lumbar (D and F) spinal cord at eight and 16 months of age. At eight months, the white matter surface-area of the lumbar spinal cord was lower in *Spg11*^*−/−*^ mice than controls and at 16 months of age, the whole spinal cord of knockout mice was atrophied (n ≥ 5 slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05 and \*\*p ≤ 0.01). (G and H) Toluidine blue-stained transverse slices of *Spg11*^*+/+*^ (G) and *Spg11*^*−/−*^ (H) mouse corticospinal tract at 16 months of age. Scale bars: 10 μm. (I and J) Toluidine blue-stained transverse slices of *Spg11*^*+/+*^ (G) and *Spg11*^*−/−*^ (H) mouse cuneate fasciculus at 16 months of age. Scale bars: 10 μm. (K and L) Distribution of corticospinal tract axons according to their section surface-area at eight (I) and 16 (J) months of age. Knockout mice displayed a lower percentage of large surface-area axons than control mice from eight months of age (n ≥ 5 slices/animal and n ≥ 10 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05 and \*\*\*p ≤ 0.001). (M) Distribution of cuneate fasciculus axons according to their section surface-area at 16 months of age (n ≥ 5 slices/animal and n ≥ 1 0 animals/genotype/age; Kruskal-Wallis test). (N) Number of dystrophic axons in a 10,000 μm^2^ area of the corticospinal tract at 4, 8, and 16 months of age (n ≥ 5 slices/animal and n ≥ 10 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001). (O) Number of dystrophic axons in a 10,000 μm^2^ area of the cuneate fasciculus at 4, 8, and 16 months of age (n ≥ 5 slices/animal and n ≥ 10 animals/genotype/age; Kruskal-Wallis test).](gr5){#f0025}

![Loss of spatacsin leads to spinal motor neuron degeneration and amyotrophy. (A and B) ChAT (red; spinal motor neuron marker) immunostaining of lumbar spinal cord slices of *Spg11*^*+/+*^ (A) and *Spg11*^*−/−*^ (B) mice at 16 months of age. Scale bars: 50 μm. (C--F) Quantitative analysis of the total number (C) and cell body area (D--F) of motor neurons per ventral horn in the lumbar spinal cord of *Spg11*^*+/+*^, *Spg11*^*+/−*^ and *Spg11*^*−/−*^ mice at 4, 8, and 16 months of age. Knockout mice displayed fewer large spinal motor neurons than controls from eight months. (n ≥ 5 slices/animal and n ≥ 10 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001). (G--I) Neuromuscular junction labeling with α-bungarotoxin (Red, postsynaptic marker) and anti-neufilament plus anti-synaptophysin antibodies (green, presynaptic markers), representing a normal Pretzel-like plaque (G) and abnormal fragmented plaques (H and I). Scale bars: 10 μm. (J) Neuromuscular junction (NMJ) surface-area in the *soleus* of *Spg11*^*+/+*^, *Spg11*^*+/−*^, and *Spg11*^*−/−*^ mice at eight and 16 months of age. (n ≥ 200 NMJ/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05; \*\*p ≤ 0.01). The NMJ surface-area of *Spg11*^*−/−*^ mice was significantly less than in control mice. (K) Percentage of fragmented NMJ in the *soleus* of *Spg11*^*+/+*^, *Spg11*^*+/−*^, and *Spg11*^*−/−*^ at 8 and 16 months of age. (n ≥ 200 NMJ/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05). *Spg11*^*−/−*^ mice exhibited a higher percentage of fragmented neuromuscular junctions than control mice. (L and M) Hematein/Eosin-stained transverse slices of the medial part of the *Spg11*^*+/+*^ (L) and *Spg11*^*−/−*^ (M) *soleus* at 16 months of age. Scale bars: 400 μm. (N and O) Total number (N) and cross-section area (O) of *soleus* myofibers from *Spg11*^*+/+*^, *Spg11*^*+/−*^, and *Spg11*^*−/−*^ mice at eight and 16 months of age (n ≥ 3 muscle slices/animal and n ≥ 5 animals/genotype/age; Kruskal-Wallis test; \*p ≤ 0.05). (P) Grip test. *Spg11*^*−/−*^ mice showed a significant loss of muscular strength in both forelimbs and hindlimbs from 12 months of age compared to control mice (n ≥ 12 animals/genotype/age; Kruskal-Wallis test; \*\*p ≤ 0.01 and \*\*\*p ≤ 0.001).](gr6){#f0030}

![Accumulation of autofluorescent particles colocalised with Lamp1 in cortical motor neurons of *Spg11*^*−/−*^ mice. (A) Lamp-1 (magenta; lysosome marker) immunostaining and autofluorescent material (green) in *Spg11*^*+/+*^ and *Spg11*^*−/−*^ cortical motor neurons from six-week and eight-month-old animals. Confocal microscopy images show autofluorescent particles surrounded by Lamp-1-positive staining in *Spg11*^*−/−*^ neurons. Scale bars: 10 μm. (B) p62 (magenta) immunostaining and autofluorescence (green) in *Spg11*^*+/+*^ and *Spg11*^*−/−*^ cortical motor neurons at six weeks, eight months, and 16 months of age. Confocal microscopy images show autofluorescent particles colocalizing with p62-positive staining only in the cortical motor neurons of 16-month-old *Spg11*^*−/−*^ mice. Scale bars: 10 μm. (C) Western blot showing levels of LC3I, LC3-II, and tubulin in extracts from *Spg11*^*+/+*^ and *Spg11*^*−/−*^ mouse cortices taken from animals of different ages. Quantification of LC3-II band intensities normalized against tubulin levels. The graph shows the mean ± SEM values. n = 3 independent samples.](gr7){#f0035}

![Loss of spatacsin promotes the accumulation of lipids in lipofuscine-like structures in neurons. (A) Electron micrographs of cortical neurons from *Spg11*^*+/+*^ and *Spg11*^*−/−*^ mice at two or 16 months. Red lines indicate the plasma membrane of neurons. Arrowheads indicate low-density structures consistent with lipid droplets. Scale bars: 5 μm (upper panels) and 1 μm (lower panels). (B) Electron micrographs of spinal cord motor neurons from two-month old *Spg11*^*+/+*^ and *Spg11*^*−/−*^ mice. Red lines indicate the plasma membrane of motor neurons. White squares indicate the zone shown at higher magnification in the insets. Scale bars: 5 μm. (C) Cathepsin D immunoelectron microscopy revealed with diaminobenzidine (DAB), showing the presence of DAB precipitates in lipofuscin-like structures (red arrowheads). Note the presence of DAB precipitates in a lysosome (red arrow). Asterisks indicate low-density structures compatible with lipid droplets. Scale bar: 500 nm. (D) Electron microscopy images of cortical neurons in the brain of an SPG11 patient (duration of disease: 10 years; age at death: 32 years), showing the accumulation of lipofuscin (arrowheads). The patient had the typical clinical features of SPG11 and carried, in *trans*, the heterozygous mutations c.2358_2359delinsTT (p.Glu786_Gly787delinsAspfs\*) in exon 13 and c.4868delT (p.Leu1623Tyrfs\*17) in exon 28. Post-mortem delay was 48 h, explaining the presence of vacuoles in the tissue. Scale bar: 2 μm.](gr8){#f0040}

![Spatacsin loss prevents the egress of lipids from lysosomes in mouse embryonic fibroblasts. (A). Electron micrographs of fibroblasts obtained from *Spg11*^*+/+*^ or *Spg11*^*−/−*^ embryos. The inset shows a higher magnification of the lysosomes indicated by the arrowheads. Note the presence of osmiophilic, undigested material in the lysosomes of *Spg11*^*−/−*^ cells. (B). Quantification of lysosome density and the mean number of lysosomes containing undigested material per μm^2^. The graph shows the means ± SEM. n \> 20 cells in two independent experiments. *t*-test; \*\*\*p ≤ 0.001. (C). Lamp1 Immunostaining (green) and Nile red staining (magenta) of primary cultures of mouse embryonic fibroblasts cultured for 0, 2, or 24 h in an amino acid-poor medium (HBSS). After 24 h in HBSS, the Nile red staining was concentrated in lipid droplets. Scale bar: 2 μm. (D). Quantification of the colocalization of Nile red staining with the lysosomal marker Lamp1 in cells cultured for 0, 2, or 24 h in an amino acid-poor medium (HBSS). The graph shows the means *±* SEM. n \> 50 cells in five independent experiments. Two-way ANOVA followed by the Holm-Sidak test; \*p ≤ 0.05. (E). Quantification of the number and size of lipid droplets. Graphs show the means ± SEM (n \> 50 cells in five independent experiments). Two-way ANOVA followed by the Holm-Sidak test; \*p ≤ 0.05; \*\*\*p ≤ 0.001.](gr9){#f0045}

![Spatacsin loss promotes lipid accumulation in lysosomes in primary cultures of cortical neurons. (A). Electron micrographs of primary cultures of cortical neurons derived from *Spg11*^*+/+*^ or *Spg11*^*−/−*^ embryos. The inset shows a higher magnification of the lysosomes indicated by arrowheads. Note the presence of undigested material in the lysosomes of *Spg11*^*−/−*^ neurons. Also, note the large number of lysosomes containing undigested material, appearing in black, in *Spg11*^*−/−*^ neurons. Scale bar: 2 μm. (B). Quantification of the mean number of lysosomes containing undigested material per μm^2^. The graph shows the means ± SEM (n \> 20 cells). *t*-test; \*\*\*p ≤ 0.001. (C). Lamp 1 immunostaining (green) and Nile red staining (magenta) of primary cultures of cortical neurons. The arrowheads indicate lipid droplets appearing as very bright structures upon Nile red staining. (D). Quantification of the colocalization of Nile red staining with the lysosomal marker Lamp1. The graph shows the means ± SEM (n \> 70 cells in four different experiments). *t*-test; \*p ≤ 0.05. (E). Number of lipid droplets per neuron in primary cultures of cortical neurons. The graph shows the means ± SEM (n \> 70 cells in four independent experiments). *t*-test; \*\*p ≤ 0.005.](gr10){#f0050}
